- Pharmaceutical services company Open Orphan said its Venn Life Sciences subsidiary had signed a contract renewal with a 'major global pharmaceutical client' worth £1.5 million over two years.

The renewed contract would commence in January, with the Venn team in Breda providing clinical pharmacokinetics support on an array of drug development programmes.

Story provided by